ProQR Therapeutics
PRQR
46 hedge funds and large institutions have $60M invested in ProQR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 15 closing their positions.
278% more capital invested
Capital invested by funds: $15.9M → $60M (+$44.1M)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
2% less funds holding
Funds holding: 47 → 46 (-1)
6.4% less ownership
Funds ownership: 29.8% → 23.4% (-6.4%)
12% less call options, than puts
Call options by funds: $655K | Put options by funds: $746K
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
+$1.19M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$554K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$455K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$426K |
| 5 |
Millennium Management
New York
|
+$247K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.17M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$1.28M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
-$1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$669K |
| 5 |
BlackRock
New York
|
-$633K |
PRQR Hedge Fund Activity: Q4 2022 in Review
46 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2022, worth a combined $60M — up 278% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PRQR and 14 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 9 added.
The largest buyer was M28 Capital Management, adding an estimated $1.19M. The largest seller was Opaleye Management, cutting an estimated $2.17M.
- 46 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2022, down from 47 in Q3 2022.
- Funds reported $60M of ProQR Therapeutics stock for Q4 2022, up 278% quarter-over-quarter.
- 14 funds opened new ProQR Therapeutics positions in Q4 2022 and 15 closed out, a net change of -1 holder.
- The largest ProQR Therapeutics buyer in Q4 2022 was M28 Capital Management, an estimated $1.19M added.
- The largest ProQR Therapeutics seller in Q4 2022 was Opaleye Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2022.